Hims & Hers Health Raises Outlook, Swings to 3Q Profit
Hims & Hers Health (HIMS.US) will launch a generic version of the old weight loss therapy of novo-nordisk a/s (NVO.US).
Hims & Hers Health CEO Andrew Dudum stated that the company is preparing to launch a non-patented version of novo-nordisk a/s's old version GLP-1 weight loss therapy liraglutide in 2025.
Hims & Hers Health Options Spot-On: On November 5th, 162.7K Contracts Were Traded, With 342.86K Open Interest
On November 5th ET, $Hims & Hers Health(HIMS.US)$ had active options trading, with a total trading volume of 162.7K options for the day, of which put options accounted for 46.37% of the total
Hims & Hers Stock Rises on Earnings and Planned Generic Version of Novo Nordisk Diabetes Drug -- Barrons.com
What's Going On With Hims & Hers Health Stock Tuesday?
Hims & Hers Core Business Looked Strong in 3Q -- Market Talk
Hims & Hers Still Benefiting From Unmet GLP-1 Demand -- Market Talk
Seaport Global Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Raises Target Price to $32
Sector Update: Health Care
TD Cowen Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $25
Charter Communications To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday
Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $28
Hims & Hers Health Analyst Ratings
A Quick Look at Today's Ratings for Hims & Hers Health(HIMS.US), With a Forecast Between $21 to $28
Social Buzz: Wallstreetbets Stocks Advance Premarket Tuesday; Palantir Technologies, Hims & Hers Health to Open Higher
Hims & Hers to Launch a Generic for Novo's Older GLP-1
Ryan MacDonald's Buy Rating on Hims & Hers Health Driven by Strong Performance and Strategic Initiatives
Hims & Hers Health (HIMS) Gets a Hold From Truist Financial
Hims & Hers Health Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Raised Its FY24 Revenue Guidance Above Estimates.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session